Professional Experience
Prof. Herishanu has held prestigious roles in clinical hematology and is currently leading one of Israel’s top hematology units.
- Current Position: Director, CLL Unit and Hematology Clinic, Tel Aviv Sourasky Medical Center (Ichilov)
- Previous Roles: Senior Hematologist at Tel Aviv Medical Center
- Academic Role: Associate Professor, Sackler Faculty of Medicine, Tel Aviv University
Academic Contributions
He is deeply involved in academic training and has contributed to clinical research and education in hematology.
- Academic Title: Associate Professor of Hematology
- University Affiliation: Sackler Faculty of Medicine, Tel Aviv University
- Conference Speaker: Regular speaker at international forums on leukemia and lymphoma
- Research Interests: CLL, B-cell signaling, targeted therapies
Areas of Expertise
Prof. Herishanu specializes in the diagnosis and treatment of complex blood-related diseases using advanced and personalized therapies.
- Chronic lymphocytic leukemia (CLL): His main area of focus
- Acute and chronic leukemias
- Lymphomas: Both Hodgkin and non-Hodgkin types
- Multiple myeloma
- Autoimmune hemolytic anemia
- Anemia and thrombocytopenia
- Bleeding disorders: Including hemophilia
Publications and Research
Prof. Herishanu has published extensively in peer-reviewed journals, advancing the understanding of CLL and innovative treatments.
- Front Immunol (2022): Explored B-cell receptor organization in CLL
- Front Oncol (2021): Demonstrated how BTK-targeting PROTACs inhibit CLL cell signaling
- J Am Chem Soc (2020): Presented innovative degradation strategies using reversible covalent PROTACs
His research supports the development of targeted treatments and novel therapeutics for CLL and related disorders.
Patient Care Philosophy
Prof. Herishanu is committed to providing empathetic, personalized care backed by the latest research. His approach focuses on building trust and tailoring treatments to each individual.
- Patient-Centered Care: Every treatment plan is customized
- Clear Communication: Ensures patients fully understand their diagnosis and therapy
- International Access: Available for pre-consultation and follow-ups online
- Languages: English, Hebrew; Russian available with interpreter
Professional Affiliations
Prof. Herishanu is part of leading national and international medical societies in hematology, reflecting his global influence in the field.
- Israeli Hematology Association
- American Society of Hematology (ASH)
- European Research Initiative on CLL (ERIC): Board Member
FAQs
- Is Prof. Yair Herishanu board-certified?
- Yes, he is board-certified in internal medicine and hematology in Israel.
- What types of treatments does he offer?
- He offers chemotherapy, immunotherapy, targeted treatments, and CAR T-cell therapy for hematologic cancers.
- Does he treat international patients?
- Yes, he welcomes international patients and offers virtual consultations with multilingual support.
- How long is the typical hospital stay for treatment?
- It varies depending on the condition. Some treatments are outpatient, while others may require extended hospitalization.
- What languages does Prof. Herishanu speak?
- He speaks Hebrew and English; Russian interpretation is available during consultations.
- Can I get a second opinion from him remotely?
- Yes, he provides remote second opinions and pre-consultations for patients worldwide.
- Does he participate in clinical trials?
- Yes, he is actively involved in CLL clinical trials and research protocols at his medical center.
